The efficacy of cannabidiol for seizures reduction in pharmacoresistant epilepsy: a systematic review and meta-analysis

被引：0

作者：

de Oliveira, Vinicius Gabino ^{[1
]}

de Almeida, Natalia Brito ^{[1
]}

Radmann, Guilherme Correa ^{[1
]}

Santos, Bruno Fernandes de Oliveira ^{[2
]}

机构：

[1] Univ Tiradentes, Med Dept, BR-49032490 Aracaju, SE, Brazil

[2] Univ Sao Paulo, Med Dept, BR-05508220 Sao Paulo, SP, Brazil

来源：

ACTA EPILEPTOLOGICA | 2025年 / 7卷 / 01期

关键词：

Epilepsy; Cannabidiol; Pharmacoresistant epilepsy; TRIAL;

D O I：

10.1186/s42494-024-00191-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

BackgroundEpilepsy is a neurological syndrome caused by excessive neuronal discharges, with a part of the patients being pharmacoresistant to the traditional treatment. Cannabidiol, a non-psychoactive component of Cannabis Sativa, shows promise as an alternative, but further research is needed to quantify its efficacy.MethodsThis literature systematic review was made following the PRISMA protocol guidelines. The Google Scholar, Scielo, and PubMed/MEDLINE databases were included using the descriptors "Cannabidiol", "Epilepsy", and "Drug Resistant Epilepsy". This research was registered in the Prospero platform with the identification (CRD42024479643).ResultsA total of 1448 results were identified from the PubMed, Virtual Health Library, and Google Scholar databases. After applying exclusion criteria, six studies met the criteria for full-text evaluation and eligibility. The compiled analysis showed that the patients who received cannabidiol experienced a 41.0875% reduction in the total number of seizures, compared to an average reduction of 18.1% in placebo groups. This represents a 127% higher response rate for patients who received the intervention.ConclusionsGiven these results, it is possible to conclude that the therapeutic response of cannabidiol is worthy of consideration in new protocols and of being added to public healthcare systems for its antiepileptic potential. However, the high efficacy rate observed in the placebo group suggests that other methods of data collection analysis may be employed.

引用

页数：8

共 11 条

[1]

Da Silva C.R.A., Sheila I., Obregon Cardoso Z., Machado N., Considerações sobre epilepsia Considerations for epilepsy, Bol Cient Pediatr, 2, 3, pp. 71-76, (2013)

[2]

da Conceicao H.C., Salino A.V., Queiroz A.K., de Ribeiro S., de O.A.E., De S.K.S.P.G.B.D.R.S., Lennox-Gastaut: relato de caso. Arch Health Invest, (2017)

[3]

Maged R., Sinha M., Koneru H.M., Sarwar H., Bandi V.V., Tarar P., Et al., Efficacy of Sodium-Glucose 2 Transporter Inhibitors in Heart Failure With Preserved Ejection Fraction: A Narrative Review, Cureus, 16, 9, (2024)

[4]

Meyer E., Bonato J.M., Mori M.A., Mattos B.A., Guimaraes F.S., Milani H., Et al., Cannabidiol confers neuroprotection in rats in a model of transient global cerebral ischemia: impact of hippocampal synaptic neuroplasticity, Mol Neurobiol, 58, 10, pp. 5338-5355, (2021)

[5]

O'Connell B.K., Gloss D., Devinsky O., Cannabinoids in treatment-resistant epilepsy: a review, Epilepsy Behav, 70, pp. 341-348, (2017)

[6]

Devinsky O., Cross J.H., Laux L., Marsh E., Miller I., Nabbout R., Et al., Trial of Cannabidiol for drug-resistant seizures in the Dravet Syndrome, N Engl J Med, 376, 21, pp. 2011-2020, (2017)

[7]

Devinsky O., Patel A.D., Thiele E.A., Wong M.H., Appleton R., Harden C.L., Et al., Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome, Neurology, 90, 14, pp. e1204-e1211, (2018)

[8]

Thiele E.A., Marsh E.D., French J.A., Mazurkiewicz-Beldzinska M., Benbadis S.R., Joshi C., Et al., Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 391, pp. 1085-1096, (2018)

[9]

Miller I., Scheffer I.E., Gunning B., Sanchez-Carpintero R., Gil-Nagel A., Perry M.S., Et al., Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome, JAMA Neurol, 77, 5, pp. 613-621, (2020)

[10]

Privitera M., Bhathal H., Wong M., Cross J.H., Wirrell E., Marsh E.D., Et al., Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: analysis from two randomized controlled trials, Epilepsia, 62, 5, pp. 1130-1140, (2021)

← 1 2 →